Onconetix Acquisition Target Realbotix Secures Streaming Series Appearance for Humanoid Robot

A pending acquisition target of Onconetix, Inc. (Nasdaq: ONCO) is expanding its commercial footprint into entertainment, a signal that humanoid robotics deployments are broadening beyond the sectors most familiar to healthcare and life sciences operators. Realbotix LLC has secured an agreement with a recognized streaming platform to feature one of its humanoid robots as a character in an upcoming episode of an Emmy-awarded television series.

The entertainment agreement adds a fifth active market for Realbotix, alongside existing deployments in education, healthcare, hospitality, and customer engagement. For those tracking AI-integrated systems entering clinical and regulated environments, the healthcare vertical remains the more consequential deployment channel, though the breadth of sectors signals commercial traction that may accelerate the acquisition timeline.

Onconetix entered into a definitive share exchange agreement on February 12, 2026, to acquire 100% of the issued and outstanding equity interests of Realbotix LLC, a wholly-owned subsidiary of Realbotix Corp., in an all-stock transaction. The combined entity is expected to trade on Nasdaq following closing, which is anticipated in the second half of 2026, subject to Onconetix shareholder approval, required regulatory approvals, and other standard closing conditions.

Realbotix's robots are designed to function as physical embodiments of AI systems while supporting digital counterparts accessible through mobile, desktop, and robotic interfaces. That architecture, spanning both physical hardware and scalable software, is the design consideration most relevant to healthcare operators evaluating AI-integrated systems for patient-facing or research applications.

Onconetix remains a commercial-stage oncology company, holding Proclarix, an in vitro diagnostic approved for sale in the European Union under the IVDR for prostate cancer, with U.S. commercialization anticipated as a lab developed test through a license agreement with Labcorp. The Realbotix acquisition represents a strategic pivot; the Registration Statement on Form S-4, which Onconetix intends to file with the SEC, will carry the proxy statement and prospectus material that shareholders and regulatory reviewers will need to assess before closing conditions are met.

The shareholder vote and SEC registration process will set the definitive timeline for when Realbotix's healthcare robotics deployments formally enter Onconetix's operational scope.

Source: Onconetix, Inc. via GlobeNewswire, August 6, 2026.